Brief: Armata Pharmaceuticals Announces New Financing And Leadership Transition
11/07/2023 13:08
July 11 (Reuters) - Armata Pharmaceuticals Inc ARMP.A :
* ARMATA PHARMACEUTICALS ANNOUNCES NEW FINANCING AND
LEADERSHIP
TRANSITION TO ACCELERATE NOVEL BACTERIOPHAGE THERAPEUTICS
* SAYS APPOINTS DEBORAH L. BIRX AS CHIEF EXECUTIVE OFFICER
* SAYS SIGNS NEW $25 MILLION CREDIT AGREEMENT AND EXTENSION
OF
EXISTING SECURED CONVERTIBLE CREDIT AGREEMENT
* SAYS DEBORAH L. BIRX WILL SUCCEED DR. BRIAN VARNUM AS
CHIEF
EXECUTIVE OFFICER OF COMPANY, EFFECTIVE IMMEDIATELY
Source text for Eikon: ID:nPn57z2wna
Further company coverage: ARMP.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Armata Pharmaceuticals
See all newsBrief: Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Delays Announcement Of Fourth Quarter And Full-Year 2025 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
Armata Pharma jumps on US FDA nod for late-stage infection trial
Brief: Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles